The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
Diabetes Care- United States
doi 10.2337/dc18-1569
Full Text
Abstract
Available in
Date
March 18, 2019
Authors
Publisher
American Diabetes Association